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Abstract
External beam radiotherapy has been playing a major role in the treatment of prostate 
cancer with excellent tumor control. Also, localization of prostate is a big challenge for 
excellent treatment, so we focus on actual IGRT techniques (ultrasound, EMF, etc.) for 
intrafraction and interfraction motion detection. We investigate several studies related 
with dose distribution of treatment planning techniques. Several studies have demon-
strated the superiority of volumetric modulated arc therapy (VMAT) plans in prostate 
cancer. We also investigate hypofractionation and stereotactic radiation outcome instead 
of conventional fractionation for prostate cancer. We mention about prostate cancer’s 
treatment in future by using MR-based linac online adaptive radiotherapy.
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1. Introduction
Prostate cancer is one of the most common cancers in the world, and the population of patients 
with intermediate-to-high-risk localized prostate cancer occupies a large proportion. Most 
prostate cancers are diagnosed at an early stage, allowing for the high rate of success with local-
ized treatment. Between 30 and 45% of men receive radiation as their primary treatment for 
prostate cancer depending on their age [1, 2]. External beam radiotherapy (EBRT) and brachy-
therapy can be used for the treatment of prostate cancer. The differences and roles of these two 
techniques rely on the physical properties of the radiation and its delivery method. The goal of 
radiotherapy treatment is to deliver a powerful dose of radiation that will kill the cancer but to 
do it as precisely as possible so that we cause minimal damage to the healthy tissue such as the 
urethra, rectum, bladder, and bowel around it. External beam radiotherapy is used as a curative 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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treatment in men with localized prostate cancer (stage T1 or T2) or with locally advanced 
disease. External beam radiotherapy can also be very helpful to men with advanced prostate 
cancer. It can ease pain in the bones and reduce the likelihood of having a fracture. Three-
dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), and 
volumetric modulated arc therapy (VMAT) techniques are all applied for this purpose.
2. Treatment planning and image-guided radiotherapy (IGRT) 
methods
The prostate and seminal vesicles are located between the rectum and the bladder. The 
position of the prostate is affected by physiologic changes in the bladder and rectum vol-
ume. These variations in position and shape can be left unchanged and compensated with 
margins or reduced by image guidance resulting in smaller irradiated volumes. Smaller 
margins reduce the dose to the organs at risk; therefore, effort has been directed at reducing 
uncertainties with the use of image guidance. Radiation oncology has seen a rapid increase 
in the use of image-guided radiotherapy (IGRT) technology for prostate cancer patients. 
Conformal high-dose radiotherapy delivered with conventional fractionation results in a 
significant biochemical control with acceptable toxicities and currently represents the stan-
dard therapy when radiotherapy is chosen as primary treatment.
2.1. Three-dimensional conformal radiotherapy (3DCRT) technique
3DCRT uses computed tomography (CT) scanning to plot exact anatomy and to come up 
with the optimal radiation dosages. 3DCRT can accurately use a patient’s unique anatomy to 
deliver radiation exactly where the patient needs it, while avoiding the bladder, rectum, ure-
thra, and bowel. Conventional 3DCRT treatment planning is manually optimized. This means 
that the treatment planner chooses all beam parameters, such as the number of beams, beam 
directions, multileaf collimators (MLCs), shapes, weights, etc., and the computer calculates 
the resulting dose distribution. 3DCRT in prostate cancer patients is a highly sophisticated 
and time-consuming method of dose delivery.
2.2. Intensity-modulated radiotherapy (IMRT) technique
In the treatment of prostate cancer, IMRT was introduced in the early 1990s at a number of cen-
ters. After advance IGRT methods were implemented to clinic, IMRT technique started to be 
more popular. IMRT, like 3DCRT, uses high-tech computer software and relies on more than 
100 digital CT scans to build a three-dimensional picture of the prostate tumor and organs at 
risks (OARs), but it can supply even more conformal dose distribution than 3DCRT. We can 
modulate the intensity of each beam during treatment with a MLC. In the case of IMRT, dose 
distribution is inversely determined, meaning that the treatment planner has to decide before 
the dose distribution he wants and the computer then calculates a group of beam intensities 
that will be produced, as nearly as possible to the desired dose distribution. We can maximize 
the dose of radiation to the tumor volume and minimize the dose that affects the healthy tissue 
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nearby. With the largest experience being detailed at the Memorial Sloan Kettering Cancer 
Center. Zelefsky et al. [3] reported on the treatment of 1571 patients with IMRT at doses as 
high as 81 Gy, with rates of gastrointestinal (GI) and genitourinary (GU) toxicity less than 
those reported from their institution for 3DCRT at similar or lower doses. Likewise, Kupelian 
et al. [4] reported results on a large study involving 770 patients treated at the Cleveland Clinic 
with intensity-modulated techniques at biologically effective doses comparable with those at 
the Memorial Sloan Kettering Cancer Center and with similar low rates of GI and GU toxicity. 
This means less collateral damage to noncancerous tissue that’s just minding its own business 
right next to the tumor in the bladder and rectum and fewer side effects.
2.3. Volumetric modulated arc therapy (VMAT) technique
Volumetric modulated arc therapy (VMAT) has attracted increasing attention because of 
its greatly improved delivery efficiency over fixed-field IMRT. Unlike IMRT, which typi-
cally includes less than 10 fixed-field beam angles, VMAT includes a large number of beam 
directions from an arc trajectory and delivers doses dynamically during rotation of the 
gantry.
VMAT is a novel radiation technique, which can achieve highly conformal dose distributions 
with improved target volume coverage and sparing of normal tissues compared with conven-
tional radiotherapy techniques. VMAT also has the potential to offer additional advantages, 
such as reduced treatment delivery time compared with conventional static-field IMRT. The 
clinical worldwide use of VMAT is increasing significantly [5].
3DCRT was incapable of covering a modern radiotherapy volume for the radical treatment of 
prostate cancer. These volumes can be treated via conventional IMRT and VMAT. VMAT was 
Figure 1. Dose distribution of prostate cancer treatment planning by using VMAT technique.
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significantly more efficient than IMRT. VMAT technologies are a superior way of delivering 
IMRT treatments [6]. VMAT treatment plan is shown in Figure 1.
VMAT has slightly better CI, while the volume of low doses was higher. VMAT had lower 
MUs than IMRT. VMAT can shorten room times and improve patient throughput over seven-
field DMLC IMRT.
2.4. Image-guided radiotherapy (IGRT) methods
Radiation oncology has seen a rapid increase in the use of image-guided radiotherapy (IGRT) 
technology for prostate cancer patients over the past decade. Prostate can move around in 
there by as much as a centimeter, depending on how full your bladder and rectum are. IGRT 
approach has a lot of flexibility, because the radiation oncologist uses CT scan images to point 
the exact location of the prostate each day.
Perirectal sparing with placement biomaterials between the posterior prostate and the ante-
rior rectum has shown promise in reducing the radiation dose received by the rectal wall 
when used in the setting of conventional fractionated radiotherapy [7, 8]. Perirectal sparing 
biomaterials may promote not only sparing of the rectum wall but also result in decreased 
dose to other organs at risk including the penile bulb and bladder (Figure 2).
Linear accelerators equipped with kilovoltage (kV) cone-beam computed tomography (CBCT) 
allow for soft tissue registration immediately before treatment over the past decade [9]. Image 
guidance was either by implanted fiducials and daily kilovoltage imaging or with the use of 
cone-beam computed tomography (CBCT). IGRT is an excellent method for dose-escalated 
external beam radiotherapy in the treatment of localized prostate cancer in regard to GU and 
GI toxicity (Figure 3).
It is well documented that the prostate bed is highly susceptible to inter-fraction motion lead-
ing to larger treatment planning margins to account for daily treatment setup uncertainties 
when matching bony anatomy. Organ motion can be a significant barrier to delivering accu-
rate external beam radiotherapy to the prostate. The use of fiducial markers in the prostate 
bed has significantly improved the accuracy of the treatment delivery.
Figure 2. MR images of perirectal sparing with biomaterials and without it.
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With CBCT scan-based correction strategies, one should be able to overcome the limitations 
of marker-based strategies. Smitsmans et al. [10] developed an automatic, rigid, three-dimen-
sional (3D) gray-value registration (3D-GR) method for fast prostate localization on CT scans. 
In a following study, they showed that the 3D-GR prostate localization also worked with 
CBCT scans and concluded that CBCT scans could be used for image-guided radiotherapy 
for prostate cancer [11]. Using the daily CBCT scans, we could compare today’s images with 
yesterday’s and tune the treatment accordingly. Many studies have been reported on image 
guidance strategies to correct for prostate motion with daily offline or online position verifi-
cation of the prostate. Most of these reports used implanted fiducial markers in the prostate 
[12, 13]. Although fiducial marker-based correction strategies are already an important step 
forward, they have some shortcomings. The implantation of markers is an invasive proce-
dure. Marker-based strategies correct for translations but tend to neglect rotations, which 
are known to be a large component of prostate motion [14]. Also, marker-based correction 
strategies do not take into account changes in position of the seminal vesicles or the effect of 
a changed anatomy on planning, especially relevant for IMRT.
The Calypso® (Varian Medical Systems, Palo Alto, USA) system uses radio-frequency waves that 
allow very accurate alignment of the prostate before each treatment session and at all times dur-
ing treatment delivery. The Calypso® system improves the ability to target radiation only to tumor 
volume, avoiding unnecessary radiation to healthy tissues such as the bladder and rectum. The 
Calypso localization and tracking system works with three Beacon® transponders, wireless elec-
tromagnetic circuits about the size of a grain of rice, that are implanted in the prostate. It is shown 
in Figure 4. The Calypso® system works with the transponders to locate the tumor’s position, 
guide the therapist to set up the treatment continuously through radiotherapy, and tailor treat-
ment delivery to trigger the beam on and off to ensure the tumor is accurately aligned throughout 
the treatment [15]. In addition, the data demonstrate that treatment with VMAT permits the use of 
advanced prostate tracking (Calypso®), resulting in similar treatment times as standard seven-field 
Figure 3. Fiducial markers image.
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dynamic multileaf collimator (DMLC) IMRT with conventional tracking [16]. Foster et al. [17] 
determined the differences between CBCT-Calypso® and kV imaging-Calypso® localizations are 
0.31 ± 1.82, 0.00 ± 1.00, and − 028 ± 1.36 and 0.28 ± 4.12, −0.28 ± 3.22, and 0.16 ± 1.61 mm, respec-
tively, in the AP, SI, and RL directions during 160 and 100 fractions each These results show good 
localization agreement between radiographic technique and electromagnetic transponder tech-
nique, indicating that each of the localization technique is suitable for prostate cancer.
The functionality of RayPilot® (Micropos Medical, Sweden) is similar to a GPS by means that 
a target is localized with given coordinates. The system communicates with an implanted 
transmitter that is located in the ROI to be treated. The transmitter sends signals to a sensor 
plate 30 times per second, and the position is presented in the software. The system consists of 
the RayPilot® receiving system which is placed on any existing treatment couch, the RayPilot 
transmitter that is placed in the ROI, and the RayPilot® software. Initially, the system is used 
in treatment of prostate cancer as IGRT system [18].
Noninvasive 4D transperineal ultrasound (4D-TPUS) has been introduced in tracking 
intrafractional prostate motion in radiotherapy. Compared to other tracking methods, the 
ultrasound has its own advantage in precise identification of the soft tissue without inva-
sive procedure or extra radiation dose. In addition, system supplies contouring tool for pros-
tate and OAR volume while doing CT/ultrasound image fusion in the same patient position. 
Clarity® (Elekta AB, Stockholm, Sweden) 4D monitoring during prostate treatment offers 
live imaging of the target and surrounding anatomy. The target position is automatically 
calculated and compared to physician action thresholds to enable intrafraction motion 
management (Figure 5).
Ultrasound provides real-time position data for the prostate that was used to gate the treat-
ment. Ultrasound motion data provides margin guidelines for clinics without ultrasound 
that treat prostate SBRT with a rectal balloon, based on their expected treatment length and 
acceptable probability of prostate excursion beyond margins. Qi et al. [19] determined the 
median (5–95% percentile) of 221 intrafraction prostate motions in the L−/R+, S+/I−, and A+/P− 
were 0.1 mm (−1.13 to 1.64 mm), −0.1 mm (−1.89 to 1.90 mm), and − 0.3 mm (−2.88 to 1.25 mm) 
by using 4D-TPUS. There were 70/221 (32%) fractions with deviation exceeding 2 mm in any 
direction, with an average duration of 26% of treatment time, while there were 19/221 (8.6%) 
Figure 4. A Beacon® transponder.
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fractions with deviation exceeding 3 mm in any direction with an average duration of 6.3% 
of treatment time. These data can help to understand the intrafraction motion of the prostate 
and may allow a reduction of treatment margin (Figure 6).
2.5. Hypofractionation radiotherapy technique
Many studies have shown a lower α/β value (1.4–3.1 Gy) for prostate cancer than most of 
other cancers. This indicates that prostate cancer would be more responsive to the size of frac-
tional dose rather than the total dose. Due to this radiobiological feature, the hypothesis is 
that  hypofractionation would yield non-inferior or even better local control than conventional 
fractionated radiotherapy without increasing the risk of treatment-related toxicities. A series 
Figure 5. Image fusion between CT and ultrasound.
Figure 6. 4D transperineal ultrasound scanning.
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of equivalent hypofractionation regimens suitable for the IMRT simultaneous integrated boost 
(SIB) were obtained for high-risk prostate cancer. For example, the conventional treatment 
regimen of 42 × 1.8 Gy (EUD = 75.4 Gy) would be equivalent to a SIB regimen of 25 × 2.54 Gy. 
Compared to the conventional two-phase treatment, the proposed SIB technique offers potential 
advantages, including better sparing of critical structures, more efficient delivery, shorter treat-
ment duration, and better biological effectiveness for high-risk prostate cancer treatment [20].
Hypofractionated image-guided radiotherapy with 15 fractions of 3.65 Gy/3 weeks is well tol-
erated with a low rate of acute and late grade ≥ 2 GI and GU toxicities. This schedule permits 
to obtain a high rate of survival and disease control with reduction of treatment time spent 
for treatment by patients [21]. Hypofractionated intensity-modulated radiotherapy of 45 Gy in 
nine consecutive fractions’ regime for mainly low−/intermediate-risk prostate cancer patients is 
favorable with low rates of late toxicity [22]. Hypofractionated radiotherapy with IMRT-IGRT as 
primary treatment for prostate cancer allows reduction in overall treatment time without com-
promising outcomes. This Hypo-IMRT with IGRT schedule for prostate radiotherapy reduces 
treatment length by 2 weeks as compared to the other treatment regimens commonly used.
Compared with conventional radiotherapy, hypofractionated radiotherapy has achieved 
similar clinical outcomes in patients with intermediate-to-high-risk localized PCa. Although 
hypofractionated radiotherapy has an increased incidence rate of acute gastrointestinal 
adverse events, the late gastrointestinal and genitourinary adverse events were similar in two 
groups and could be tolerable for the patients.
2.6. Stereotactic body radiotherapy (SBRT) technique
Stereotactic body radiotherapy (SBRT) is an established treatment technique for prostate 
cancer. High dose per fraction radiotherapy has theoretical advantages when treating “late 
responding tissue.” SBRT for high-risk prostate cancer (PCa) remains investigational not only 
due to concerns for potential toxicity when the treatment volumes extend beyond the prostate 
gland itself. Specifically, some investigators have reported high rates of toxicity when target-
ing elective pelvic nodal irradiation volumes with SBRT techniques, but technical consider-
ations may have influenced those results. SBRT regimes can be safely used to treat patients 
with high-risk PCa in a total of 5 treatment days. The addition of pelvic nodal radiation did 
not significantly increase acute or late genitourinary or gastrointestinal toxicity on either phy-
sician- or patient-reported scales [23].
Dose escalation beyond currently standard SBRT regimens may further improve outcomes, 
particularly for bulkier tumors, but could be limited by organ dose constraints. However, 
selective dose escalation to identified regions of high tumor burden may offer a safer approach 
than uniform dose escalation, thereby maximizing therapeutic ratio. Therefore, this ongoing 
prospective study seeks to test the planning and delivery feasibilities and the tolerability of 
treating patients with a modest dose escalation to the entire prostate and a SIB to magnetic 
resonance (MR)-identified lesions (Figure 7).
Chapet et al. [24] compared acute toxicities of moderate hypofractionation versus stereotac-
tic radiation for prostate cancer. They determined that hypofractionation and SBRT are well 
tolerated in only two grade 3 acute GU toxicities and only one grade 3 GI toxicity. There is no 
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difference in grade ≥ 2 acute toxicities, the acute profile of tolerance appears to be the same 
between hypofractionation and SBRT for urinary toxicities, and acute GI toxicities seem to be 
well controlled by the spacer whatever fractionation is used.
SBRT for prostate cancer has become increasingly popular, but the use of hypofraction-
ation necessitates special consideration of the normal tissue tolerances of organs such as 
the urethra, bladder, and rectum. Tracking prostatic motion in real time provides more 
precise treatment by allowing a repositioning of the treatment couch if the fiducials move 
outside a threshold margin. Although soft tissue anatomy is not readily visualized in real 
time during treatment, fiducial marker position is used as a surrogate for target/organ-at-
risk geometry. Because of the observed random distribution of motion, we hypothesize 
that CBCT’s performed before and after treatment may miss intrafraction movements that 
exceed the threshold margin. Due to intrafractional movement, positioning the patient 
exclusively based on the pretreatment CBCT scans is insufficient to ensure complete target 
coverage. Intrafractional on-demand imaging is required to ensure adequate coverage to 
the PTV.
Robotic SBRT of soft tissue lesions using Cyberknife® (Accuray, Sunnyvale, USA) requires 
implantation of fiducial markers for target tracking by the stereoscopic KV X-ray imaging system. 
The spatial distribution of the fiducials must allow accurate calculation of 3D transformation 
that describes the position of the prostate within the reference frame of the planning CT scan. 
Poor fiducial placement limits accurate tracking. Creating fiducial implantation protocol 
could improve ability to accurately track prostate motion during treatment. In order to take 
into account intrafraction rotation, a minimal spacing of 1.8 cm must be achieved between 
Figure 7. Prostate SBRT treatment by using 4D TPUS Clarity® IGRT system and versa HD® linear accelerator.
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implanted markers. This is frequently accomplished with double-loaded needles with spacers 
present or rigidly attached to the markers.
Advanced IGRT methods such as ultrasound, EMF, etc. with perirectal sparing biomaterials 
and/or fiducial markers can supply significantly advantage for accurate hypofractionation 
and SBRT treatment of prostate cancer.
Protons have completely different dose distribution properties and have the potential to 
avoid most of the extra-target radiation that is inherent to photons. Unlike a photon, a proton 
is a heavy particle (roughly 1800 times the mass of an electron) with an elementary charge, 
which confers certain dosimetric advantages. Heavy particles, as opposed to photons, will 
stop within a target. This unique property allows protons to be targeted so that they have 
their most damaging effects in the tumor itself, with less radiation delivered in front of the 
target, and no dose delivered beyond it. This peak of energy delivery is commonly referred to 
as the Bragg peak. It is shown in Figure 8. The Bragg peak is very narrow and must be spread 
out using multiple proton energies to ensure that the peak encompasses the entire target.
Proton beam therapy for prostate cancer has become a source of controversy in the urologic 
community, and the rapid dissemination and marketing of this technology have led to many 
patients inquiring about this therapy. Several groups [25–30] have investigated the dosimetric 
quality of proton therapy for prostate cancer. Rana et al. [31] determined the average differ-
ence in the PTV doses between the VMAT and lateral two-field proton plans was within ±1%. 
On average, the proton plans produced a lower mean dose to the rectum (18.2 Gy (relative 
biological effectiveness [RBE]) vs. 40.0 Gy) and bladder (15.8 Gy (RBE) vs. 30.1 Gy), whereas 
the mean dose to the femoral heads was lower in the VMAT plans (28.3 Gy (RBE) vs. 19.3 Gy).
Magnetic resonance images (MRI) demonstrate superior soft tissue contrast such as the pros-
tate, rectum, bladder, etc. than CT scans. MR based-linac offers a clinically proven on-table 
MRI-guided online adaptive, automated and integrated treatment planning system that uses 
a linac to deliver modulated radiotherapy. Magnetic resonance radiotherapy (MR/RT)  system 
is capable of delivering precisely targeted radiation doses while simultaneously captur-
ing magnetic resonance (MR) images. We expect significantly decreased target margin and 
increased target dosage by using online adaptive MRI-based linac in the future (Figure 9).
Figure 8. Depth dose curves of electron, photon, proton, and carbon beams.
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